Mayo Clinic Proceedings Home

Kidney Function After the First Kidney Stone Event

Published:October 25, 2016DOI:



      To determine whether there is a persistent decline in kidney function after the first kidney stone event.

      Patient and Methods

      Incident symptomatic stone formers and age- and sex-matched controls underwent 2 study visits 90 days apart to assess kidney function, complete a survey, and have their medical records reviewed. Kidney function was compared between stone formers and controls adjusting for clinical, blood, and urine risk factors.


      There were 384 stone formers and 457 controls. At visit 1, a median of 104 days after the stone event, stone formers compared with controls had similar serum creatinine (0.86 vs 0.84 mg/dL; P=.23), higher serum cystatin C (0.83 vs 0.72 mg/L; P<.001), higher urine protein (34.2 vs 19.7 mg/24 h; P<.001) levels, and were more likely to have albuminuria (24 h urine albumin >30 mg: 5.4% vs 2.2%; P=.02). Findings were similar after adjustment for risk factors and at visit 2, a median of 92 days after visit 1. In the 173 stone formers with serum creatinine levels from care before study participation, the mean serum creatinine level was 0.84 mg/dL before the stone event, increased to 0.97 mg/dL (P<.001) at the stone event, but returned to 0.85 mg/dL (P=.38) after the stone event (visit 1).


      Incident symptomatic stone formers have a rise in serum creatinine levels that resolves. However, stone formers have sustained higher cystatin C levels and proteinuria that may affect long-term risk of chronic kidney disease.

      Abbreviations and Acronyms:

      CKD (chronic kidney disease), eGFRCr (serum creatinine–based estimated glomerular filtration rate), GFR (glomerular filtration rate), OR (odds ratio)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Scales Jr., C.D.
        • Smith A.C.
        • Hanley J.M.
        • Saigal C.S.
        Prevalence of kidney stones in the United States.
        Eur Urol. 2012; 62: 160-165
        • El-Zoghby Z.M.
        • Lieske J.C.
        • Foley R.N.
        • et al.
        Urolithiasis and the risk of ESRD.
        Clin J Am Soc Nephrol. 2012; 7: 1409-1415
        • Rule A.D.
        • Bergstralh E.J.
        • Melton III, L.J.
        • Li X.
        • Weaver A.L.
        • Lieske J.C.
        Kidney stones and the risk for chronic kidney disease.
        Clin J Am Soc Nephrol. 2009; 4: 804-811
        • Shoag J.
        • Halpern J.
        • Goldfarb D.S.
        • Eisner B.H.
        Risk of chronic and end stage kidney disease in patients with nephrolithiasis.
        J Urol. 2014; 192: 1440-1445
        • Alexander R.T.
        • Hemmelgarn B.R.
        • Wiebe N.
        • et al.
        Kidney stones and kidney function loss: a cohort study.
        BMJ. 2012; 345: e5287
        • Hippisley-Cox J.
        • Coupland C.
        Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores.
        BMC Fam Pract. 2010; 11: 49
        • Kummer A.E.
        • Grams M.
        • Lutsey P.
        • et al.
        Nephrolithiasis as a risk factor for CKD: the Atherosclerosis Risk in Communities Study.
        Clin J Am Soc Nephrol. 2015; 10: 2023-2029
        • Torricelli F.C.
        • De S.K.
        • Gebreselassie S.
        • Li I.
        • Sarkissian C.
        • Monga M.
        Dyslipidemia and kidney stone risk.
        J Urol. 2014; 191: 667-672
        • Reiner A.P.
        • Kahn A.
        • Eisner B.H.
        • et al.
        Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study.
        J Urol. 2011; 185: 920-925
        • Lorenz E.C.
        • Lieske J.C.
        • Vrtiska T.J.
        • et al.
        Clinical characteristics of potential kidney donors with asymptomatic kidney stones.
        Nephrol Dial Transplant. 2011; 26: 2695-2700
        • Rule A.D.
        • Lieske J.C.
        • Li X.
        • Melton III, L.J.
        • Krambeck A.E.
        • Bergstralh E.J.
        The ROKS nomogram for predicting a second symptomatic stone episode.
        J Am Soc Nephrol. 2014; 25: 2878-2886
        • Rocca W.A.
        • Yawn B.P.
        • St Sauver J.L.
        • Grossardt B.R.
        • Melton III, L.J.
        History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population.
        Mayo Clin Proc. 2012; 87: 1202-1213
        • Improving Global Outcomes (KDIGO) CKD Work Group
        KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease.
        Kidney Int Suppl. 2013; 3: 1-150
        • Rule A.D.
        • Glassock R.J.
        GFR Estimating equations: getting closer to the truth?.
        Clin J Am Soc Nephrol. 2013; 8: 1414-1420
        • Rule A.D.
        • Bailey K.R.
        • Lieske J.C.
        • Peyser P.A.
        • Turner S.T.
        Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease.
        Kidney Int. 2013; 83: 1169-1176
        • Shlipak M.G.
        • Matsushita K.
        • Arnlov J.
        • et al.
        Cystatin C versus creatinine in determining risk based on kidney function.
        N Engl J Med. 2013; 369: 932-943
        • Singh P.
        • Enders F.T.
        • Vaughan L.E.
        • et al.
        Stone composition among first-time symptomatic kidney stone formers in the community.
        Mayo Clin Proc. 2015; 90: 1356-1365
        • Worcester E.M.
        • Parks J.H.
        • Evan A.P.
        • Coe F.L.
        Renal function in patients with nephrolithiasis.
        J Urol. 2006; 176 (discussion 603): 600-603
        • Saucier N.A.
        • Sinha M.K.
        • Liang K.V.
        • et al.
        Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota.
        Am J Kidney Dis. 2010; 55: 61-68
        • Jungers P.
        • Joly D.
        • Barbey F.
        • Choukroun G.
        • Daudon M.
        ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention.
        Am J Kidney Dis. 2004; 44: 799-805
        • Viers B.R.
        • Lieske J.C.
        • Vrtiska T.J.
        • et al.
        Endoscopic and histologic findings in a cohort of uric acid and calcium oxalate stone formers.
        Urology. 2015; 85: 771-776
        • Ahmadi F.
        • Etemadi S.M.
        • Lessan-Pezeshki M.
        • et al.
        Contribution of stone size to chronic kidney disease in kidney stone formers.
        Int J Urol. 2015; 22: 104-108
        • Vedovato M.
        • Lepore G.
        • Coracina A.
        • et al.
        Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance.
        Diabetologia. 2004; 47: 300-303
        • Pearle M.S.
        • Goldfarb D.S.
        • Assimos D.G.
        • et al.
        Medical management of kidney stones: AUA guideline.
        J Urol. 2014; 192: 316-324
        • Rule A.D.
        • Krambeck A.E.
        • Lieske J.C.
        Chronic kidney disease in kidney stone formers.
        Clin J Am Soc Nephrol. 2011; 6: 2069-2075
        • Bucaloiu I.D.
        • Kirchner H.L.
        • Norfolk E.R.
        • Hartle II, J.E.
        • Perkins R.M.
        Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury.
        Kidney Int. 2012; 81: 477-485
        • Klahr S.
        New insights into the consequences and mechanisms of renal impairment in obstructive nephropathy.
        Am J Kidney Dis. 1991; 18: 689-699
        • Foley R.N.
        • Wang C.
        • Collins A.J.
        Cystatin C, mortality risk and clinical triage in US adults: threshold values and hierarchical importance.
        Nephrol Dial Transplant. 2011; 26: 1831-1837